Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-05-09
2010-10-26
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S004100, C536S017200, C536S017400, C536S017500, C536S017800
Reexamination Certificate
active
07820627
ABSTRACT:
The core structure of pentaerythritol has been used as a replacement for one or both sugars in lipid A, leading to the generation of a series of lipid A analogs. These lipid A analogs may further differ from lipid A with respect to, e.g., the number, nature and location of negatively charged groups, and the number, nature and location of the lipid chains. The lipid A analogs may be lipid A agonists useful as immunostimulatory agents, or lipid A antagonists useful in the treatment of septic shock. In a like manner, a residue of pentaerythritylamine may be used as a replacement for an amino sugar residue in a carbohydrate ligand having a biological activity of interest, generating a series of ligand analogs. These are useful, e.g., as haptens, inhibitors of bacterial-host cell adhesion, etc.
REFERENCES:
patent: 3930024 (1975-12-01), Creger
patent: 4464383 (1984-08-01), Yamamoto
patent: 4719202 (1988-01-01), van Boeckel et al.
patent: 4912094 (1990-03-01), Myers et al.
patent: 5041427 (1991-08-01), Takayama et al.
patent: 5191072 (1993-03-01), Hasegawa et al.
patent: 6113918 (2000-09-01), Johnson et al.
patent: 6136790 (2000-10-01), Toepfer et al.
patent: 6316421 (2001-11-01), Nantz et al.
patent: 6699846 (2004-03-01), Elliott et al.
patent: 6764840 (2004-07-01), Johnson et al.
patent: 906 808 (1954-03-01), None
patent: 0 122 151 (1989-02-01), None
patent: 58-10592 (1983-01-01), None
patent: 63-139186 (1988-06-01), None
patent: WO 86/05687 (1986-10-01), None
patent: WO 95/01966 (1995-01-01), None
patent: WO 95/27505 (1995-10-01), None
patent: WO 01/36433 (2001-05-01), None
patent: WO 01/79243 (2001-10-01), None
patent: WO 03/066649 (2003-08-01), None
patent: WO 03/089574 (2003-10-01), None
Beilstein Abstract, Registry #4885466 (underlying reference 1992).
Beilstein Abstract, Registry #1776862 (underlying reference 1952).
Beilstein Abstract, Registry #1777272 (underlying reference 1953).
Beilstein Abstract, Registry #2299756 (underlying reference 1971).
Beilstein Abstract, Registry #2450963 (underlying reference 1979).
Beilstein Abstract, Registry #2478491 (underlying reference 1979).
Beilstein Abstract, Registry #4386563 (underlying reference 1981).
Beilstein Abstract, Registry #4438100 (underlying reference 1981).
Beilstein Abstract, Registry #4866378 (underlying reference 1992).
Beilstein Abstract, Registry #3310799 (underlying reference 1937.
Beilstein Abstract, Registry #3433270 (underlying reference 1937).
Beilstein Abstract, Registry #7349279 (underlying reference 1988).
Beilstein Abstract, Registry #7349664 (underlying reference 1988).
Beilstein Abstract, Registry #299061 (underlying reference 1950).
Beilstein Abstract, Registry #6129710 (underlying reference 1966).
Beilstein Abstract, Registry #6129784 (underlying reference 1966).
Beilstein Abstract, Registry #1817997, entry date Jun. 29, 1989.
Beilstein Abstract, Registry #1894672, entry date Jun. 29, 1989.
Beilstein Abstract, Registry #2271917, entry date Jun. 29, 1989.
Beilstein Abstract, Registry #1842361, entry date Jun. 29, 1989.
Beilstein Abstract, Registry #2289689, entry date Jun. 29, 1989.
Beilstein Abstract, Registry #2301356, entry date Jun. 29, 1989.
Beilstein Abstract, Registry #4360897, entry date Dec. 2, 1991.
Beilstein Abstract, Registry #7682492, entry date Jul. 31, 1997.
Beilstein Abstract, Registry #7682309, entry date Jul. 31, 1997.
Beilstein Abstract, Registry #7684107, entry date Jul. 31, 1997.
Beilstein Abstract, Registry #7683736, entry date Jul. 31, 1997.
Aguilera, et al., “Novel Disaccharide Inhibitors of Human Glioma Cell Division”,J. Med. Chem., vol. 41, pp. 4599-4606, 1998.
Armspach, et al., “Boron-rich metallodendrimers-mix and-match assembly of multifunctional metallosupramolecules”,Chem. Commun., vol. 15, pp. 1823-1824, 1996.
Charon, et al., “Chemical synthesis and Immunological Activities of Glycolipids Structurally Related to Lipid A”,Biochemistry, vol. 24, pp. 2736-2742, 1985.
Cheng, et al., “Molecular Design of Liquid-Crystalline Block Molecules: Semifluorinated Pentaerythritol Tetrabenzoates Exhibiting Lamellar, Columnar, and Cubic Mesophases”,Angew. Chem. Int. Ed., vol. 39, No. 3, pp. 592-595, 2000.
Christ, et al., “E5531, a Pure Endotoxin Antagonist of High Potency”,Science, vol. 268, pp. 80-83, Apr. 7, 1995.
Donnerstag, et al., “A Structurally and Biogenetically Interesting Moenomycin Antibiotic”,Tetrahedron, vol. 51, No. 7, pp. 1931-1940, 1995.
Dunn, et al., “Versatile Methods for the Synthesis of Differentially Functionalized Pentaerythritol Amine Derivatives”,J. Org. Chem., vol. 55, pp. 6368-6373, 1990.
El-Abadla, et al., “Moenomycin A: The Role of the Methyl Group in the Moenuronamide Unit and a General Discussion of Structure-Activity Relationships”,Tetrahedron, vol. 55, pp. 699-722, 1999.
Farcy, et al., “A Pentaerythritol-Based Molecular Scaffold for Solid-Phase Combinatorial Chemistry”,Organic Letters, vol. 3, No. 26, pp. 4299-4301, 2001.
Fehlhaber, et al., “Moenomycin A: A Structural Revision and New Structure-Activity Relations”,Tetrahedron, vol. 46, No. 5, pp. 1557-1568, 1990.
Ferse, et al., “Acceptor Site Recognition of Transglycosylase Inhibitors A β-D-glucopyranosyl-(1-2)-α-D-glucopyranuronamide-derived Moenomycin Analogue”, Tetrahedron, vol. 55, pp. 3749-3766, 1999.
Fujishima, et al., “New synthetic immunomodulators combining a 4-O-phosphono-D-glucos-amine derivative related to bacterial lipid A with 1-deoxy-N-acetylmuramoyl dipeptide analogs”,Carbohydrate Research, vol. 167, pp. 317-324, 1987.
Goldman, et al., “Differential Antibacterial Activity of Moenomycin Analogues on Gram-Positive Bacteria”,Bioorganic&Medicinal Chemistry Letters, vol. 10, pp. 2251-2254, 2000.
Hanessian, et al., “Synthesis of clustered D-GalNAc (Tn) and D-Galβ(1-3)GalNac (T) antigenic motifs using a pentaerythritol scaffold”,Can. J. Chem., vol. 74, pp. 1738-1747, 1996.
Hebler-Klintz, et al., “The First Moenomycin Antibiotic Without The Methyl-Branched Uronic Acid Constituent. - Unexpected Structure Activity Relations”,Tetrahedron, vol. 49, No. 35, pp. 7667-7678, 1993.
Hohgardt, et al., “Synthesis of Two Structural Analogues of the Smallest Antibiotically Active Degradation Product of Moenomycin A”,Tetrahedron, vol. 44, No. 18, pp. 5771-5790, 1988.
Imoto, et al., “Chemical Structure ofEscherichia coliLipid A”,Tetrahedron Letters, vol. 26, No. 7, pp. 907-908, 1985.
Imoto, et al., “Total Synthesis ofEscherichia coliLipid A”,Tetrahedron Letters, vol. 26, No. 12, pp. 1545-1548, 1985.
Jiang, et al., “Novel lipid A mimetics derived from pentaerythritol: synthesis and their potent agonistic activity”,Tetrahedron, vol. 58, pp. 8833-8842, 2002.
Jiang, et al., “Synthetic Vaccines: The Role of Adjuvants in Immune Targeting”,Current Medicinal Chemistry, vol. 10, pp. 1423-1439, 2003.
Kiso, et al., “Synthesis of 2-Deoxy-4-O-Phosphono-3-O-Tetradecanoyl-2-[(3R)-And (3S)-3-Tetradecanoyloxytetradecanamido] -D-Glucose: A Diastereoisomeric Pair of 4-O-Phosphono-D-Glucosamine Derivatives (GLA-27) Related to Bacterial Lipid A”,Carbohydrate Research, vol. 148, pp. 221-234, 1986.
Kotani, et al., “Immunobiological Activities of Synthetic Lipid A Analogs with Low Endotoxicity”,Infection and Immunity, vol. 54, No. 3, pp. 673-682, Dec. 1986.
Kotani, et al., “Low Endotoxic Activities of SyntheticSalmonella-Type Lipid A with an Additional Acyloxyacyl Group on the 2-Amino Group of β(1-6)Glucosamine Disaccharide 1, 4′-Bisphosphate”,Infection and Immunity, vol. 52, No. 3, pp. 872-884, Jun. 1986.
Kutuzova, et al., “Diphosphoryl Lipid A fromRhodobacter sphaeroidesBlcks the Binding and Internalization of Lipopolysaccharide in RAW 264.7 Cells”,The Journal of Immunology, vol. 167, pp. 482-489, 2001.
Kuzdzal, et al., “Dendrimer Electrokinetic Capillary Chromatog
Budzynski Wladyslaw
Jiang Zi-Hua
Koganty R. Rao
Oncothyreon Inc.
Peselev Elli
Wilson Sonaini Goodrich & Rosati
LandOfFree
Lipid A and other carbohydrate ligand analogs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipid A and other carbohydrate ligand analogs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid A and other carbohydrate ligand analogs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4230287